Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome Yee-Jen WuChien-Chih WuChi-Chuan Wang OriginalPaper 31 March 2024 Pages: 537 - 546
Antithrombotic strategies for preventing graft failure in coronary artery bypass graft Maria Sara MauroSimone FinocchiaroDavide Capodanno ReviewPaper Open access 16 March 2024 Pages: 547 - 557
Impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease patients complicated with end-stage renal disease Zekang YeQin WangChunjian Li OriginalPaper Open access 23 February 2024 Pages: 558 - 565
Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory Paul A. GurbelKevin BlidenUdaya S. Tantry OriginalPaper 13 March 2024 Pages: 566 - 575
Impact of rise and fall phases of shear on platelet activation and aggregation using microfluidics Xuemei GaoTiancong ZhangYuan Li OriginalPaper 31 March 2024 Pages: 576 - 586
A systematic review of therapeutic enoxaparin dosing in obesity Maya R. ChilbertKimberly ZammitAshley E. Woodruff ReviewPaper 25 February 2024 Pages: 587 - 597
Management of direct oral anticoagulant drug interactions in hospitalized patients Mohsen H. Al ZariaLeo F. BuckleyJohn Fanikos OriginalPaper 30 March 2024 Pages: 598 - 602
Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity Jeffrey D. SperryAletha LoebJennifer A. Szwak OriginalPaper 26 February 2024 Pages: 603 - 612
Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa Julius Chacha MwitaJoel Msafiri FrancisKaren Cohen OriginalPaper Open access 13 March 2024 Pages: 613 - 621
One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke Yasutaka MurakamiKenichi TodoHideki Mochizuki OriginalPaper Open access 31 March 2024 Pages: 622 - 629
The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review L. Al-TourahS. MithoowaniRick Ikesaka OriginalPaper 01 March 2024 Pages: 630 - 637
Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database Bang TruongLori HornsbyJingjing Qian OriginalPaper Open access 20 March 2024 Pages: 638 - 649
Superficial vein thrombosis and its relationship with malignancies: a prospective observational study Alejandro Díez-VidalJavier Gómez LópezYale Tung-Chen OriginalPaper 16 March 2024 Pages: 650 - 657
A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants Benjamin WeeJeffrey LaiBrandon Lui OriginalPaper 23 February 2024 Pages: 658 - 667
Prediction of mortality in acute pulmonary embolism in cancer-associated thrombosis (MAUPE-C): derivation and validation of a multivariable model Mario AramberriJesús González-OlmedoCarmen Diaz-Pedroche OriginalPaper 14 March 2024 Pages: 668 - 676
Management of DOAC-related bleeding in cancer patients: a single center-case series Sophia LeeJeremy A. RossCristhiam M. Rojas Hernandez OriginalPaper 31 March 2024 Pages: 677 - 682
Discrimination of the acute pulmonary embolism subtypes based on the novel MAPH score Onur AkhanMustafa BozMehmet Kis OriginalPaper 28 February 2024 Pages: 683 - 690
Is a minimum duration of 5 days of unfractionated heparin infusion necessary before transition to oral anticoagulation in cerebral venous thrombosis? a retrospective chart review Ariel N. CarrionTeresa A. AllisonSophie Samuel OriginalPaper 28 February 2024 Pages: 691 - 698
Therapeutic implication of MicroRNA-320a antagonist in attenuating blood clots formed during venous thrombosis Swati SrivastavaIti GargRajeev Varshney OriginalPaper 23 February 2024 Pages: 699 - 709
Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry Omri CohenGili Kenetand the RIETE investigators OriginalPaper 16 March 2024 Pages: 710 - 720
Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity Erica OkazakiBárbara Gomes BarionFernanda Andrade Orsi OriginalPaper 25 March 2024 Pages: 721 - 729
COVID-19 vaccination affects short-term anti-coagulation levels in warfarin treatment Li-Hua LiuYang-Zhao ZhouSheng-Lan Tan OriginalPaper 25 March 2024 Pages: 730 - 738
Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate Richard J BukaDavid J SuttonPhillip LR Nicolson Letter to the Editor 15 February 2024 Pages: 739 - 741